YUHSpace: Hong, Min Hee

Browsing by Yonsei Author : Hong, Min Hee

eperson profile image
Name:
Hong, Min Hee [홍민희]
orcid http://orcid.org/0000-0003-3490-2195
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (57191958755)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 105

This table browses all dspace content
Issue DateTitleJournal Title
2024Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea Lung Cancer : targets and therapy
2024Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort studyCANCER LETTERS
2024Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma CANCER RESEARCH COMMUNICATIONS
2024Single-cell analysis reveals cellular and molecular factors counteracting HPV-positive oropharyngeal cancer immunotherapy outcomes JOURNAL FOR IMMUNOTHERAPY OF CANCER
2024A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12) ONCOIMMUNOLOGY
2024A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell CarcinomaCLINICAL CANCER RESEARCH
2024Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy response THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2024Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLCCLINICAL CANCER RESEARCH
2024Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types FRONTIERS IN IMMUNOLOGY
2024Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH TrialJOURNAL OF CLINICAL ONCOLOGY
2024Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2024Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma CANCER RESEARCH AND TREATMENT
2024SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer JOURNAL OF CLINICAL ONCOLOGY
2023Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer LUNG CANCER
2023Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies CANCERS
2023Dynamic change of immune phenotype assessed by artificial intelligence (AI)-powered analysis of tumor-infiltrating lymphocytes (TILs) during neoadjuvant durvalumab with or without tremelimumab (D+/-T) in head and neck squamous cell carcinoma (HNSCC) JOURNAL OF CLINICAL ONCOLOGY
2023Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy TRANSLATIONAL LUNG CANCER RESEARCH
2023Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancerNATURE CANCER
2023Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea Cancer Treatment and Research Communications
2023Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter studyLUNG CANCER
2023Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing CANCER RESEARCH AND TREATMENT
2023Clinical Outcomes of Thymic Carcinoma: The Role of Radiotherapy Combined with Multimodal Treatments CANCERS
2023Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea DRUGS-REAL WORLD OUTCOMES
2023The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer KOREAN JOURNAL OF INTERNAL MEDICINE
2023A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation CANCER
2023Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCCLINICAL CANCER RESEARCH
2022Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment FRONTIERS IN CHEMISTRY
2022Treatment outcomes and radiotherapy deintensification strategies in human papillomavirus-associated tonsil cancer RADIATION ONCOLOGY
2022Role of postoperative radiotherapy in resected adenoid cystic carcinoma of the head and neck RADIATION ONCOLOGY
2022The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report ESMO OPEN
2022A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)CLINICAL CANCER RESEARCH
2022Lazertinib: on the Way to Its Throne YONSEI MEDICAL JOURNAL
2022Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22 TRANSLATIONAL LUNG CANCER RESEARCH
2022Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation THERANOSTICS
2022Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experienceCANCER IMMUNOLOGY IMMUNOTHERAPY
2022A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors JOURNAL OF THORACIC ONCOLOGY
2022Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity FRONTIERS IN ONCOLOGY
2022Disproportional enrichment of FoxP3(+)CD4(+) regulatory T cells shapes a suppressive tumourmicroenvironment in head and neck squamous cell carcinoma CLINICAL AND TRANSLATIONAL MEDICINE
2022Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapyRADIOTHERAPY AND ONCOLOGY
2022The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges FRONTIERS IN ONCOLOGY
2022SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models CLINICAL & TRANSLATIONAL IMMUNOLOGY
2022Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor YONSEI MEDICAL JOURNAL
2022The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer EXPERIMENTAL AND MOLECULAR MEDICINE
2022Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2021Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents KIDNEY RESEARCH AND CLINICAL PRACTICE
2021Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patientsJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2021Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2021Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER

Browse

Links